CAMP4 Therapeutics Corporation
NASDAQ:CAMPBiotechnology
+$0.10 today
- Market cap
- $257.29M
- Beta
- 0.08
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$1.49
Volume 0.19M
Average 0.10M
CAMP Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
CAMP4 Therapeutics CorporationNASDAQ: CAMP
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses dips below year-ago levels
Q1 FY2026 operating expenses of $13.85M fell 0.8% year over year, behind the +0.4% change in trailing-twelve-month operating expenses. Sequentially, it rose 5.5% from the prior quarter.
Context
- Operating expenses amounted to 1541.5% of revenue in FY2025, down 6700.9 pp from a year earlier.
- Operating expenses increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -0.8% toward the trailing-twelve-month pace of +0.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 53.92M USD
- Year-over-year change
- +0.3%
- 4-year CAGR
- -20.5%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 53.92M | +0.3% |
| FY2024 | 2024-12-31 | 53.74M | +2.9% |
| FY2023 | 2023-11-30 | 52.23M | +16.1% |
| FY2022 | 2023-02-28 | 45M | -66.6% |
| FY2021 | 2022-02-28 | 134.76M | — |
Operating Expenses vs competitors
How CAMP compares with its peers on the latest reported figures
- Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +0.4% is the 2nd highest of 9, against a peer median of -6.3%.
- Operating expenses amounts to 1398.8% of revenue for CAMP, versus a peer median of 125.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $217.43M USD | +108.0% | +24.1% | 85.1% | |
| LTM Mar 2026 | $91.02M USD | -33.2% | -6.5% | — | |
| LTM Mar 2026 | $83.6M USD | -5.5% | +4.1% | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $82.58M USD | -10.8% | +36.3% | — |
| LTM Mar 2026 | $65.98M USD | -50.3% | -1.5% | — | |
| LTM Mar 2026 | $55.03M USD | +0.4% | — | 1398.8% | |
| LTM Mar 2026 | $50.96M USD | -7.1% | +11.4% | 26818.9% | |
| LTM Mar 2026 | $29.76M USD | -3.7% | +15.1% | — | |
HYFTMindWalk Holdings Corp. | LTM Jan 2026 | CA$23.06M CAD | -5.4% | -2.4% | 125.6% |
| Peer median (excluding CAMP) | — | -6.3% | +7.8% | 125.6% | |
Competitors are the stored peer set for CAMP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Feb 2022 | FY2022 Feb 2023 | FY2023 Nov 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 295.84M | 0 | 350K | 652K | 3.5M |
| Cost of Revenue | 173.95M | 0 | 0 | 0 | 1.64M |
| Gross Profit | 121.89M | (947K) | 350K | 652K | 1.86M |
| Gross Margin | 41.2% | — | 100.0% | 100.0% | 53.1% |
| Research & Development | 28.44M | 34.77M | 40.62M | 38.82M | 38.2M |
| Selling, General & Admin | 100.9M | 10.23M | 11.61M | 14.92M | 17.36M |
| Operating Expenses | 134.76M | 45M | 52.23M | 53.74M | 53.92M |
| Depreciation & Amortization | 22.8M | 878K | 1.68M | 1.7M | 1.64M |
| EBITDA | 7.49M | (44.12M) | (50.2M) | (51.39M) | (50.42M) |
| EBITDA Margin | 2.5% | — | -14343.1% | -7882.2% | -1441.5% |
| Operating Income | (15.31M) | (45M) | (51.88M) | (53.09M) | (52.06M) |
| Operating Margin | -5.2% | — | -14822.6% | -8142.3% | -1488.3% |
| Interest Income | 0 | 0 | 2.81M | 1.33M | 2.17M |
| Interest Expense | 15.32M | 6.26M | 0 | 0 | 0 |
| Other Income / Expenses | (14.75M) | 809K | 2.59M | 1.3M | (28.34M) |
| Income Before Tax | (30.06M) | (44.19M) | (49.29M) | (51.79M) | (80.4M) |
| Pre-Tax Margin | -10.2% | — | -14083.1% | -7943.4% | -2298.5% |
| Income Tax Expense | 1.09M | 0 | 0 | 0 | 0 |
| Net Income | (31.15M) | (44.19M) | (49.29M) | (51.79M) | (80.4M) |
| Net Margin | -10.5% | — | -14083.1% | -7943.4% | -2298.5% |
| EPS (Basic) | (0.88) | (0.90) | (4.07) | (2.66) | (2.65) |
| EPS (Diluted) | (0.88) | (0.90) | (4.07) | (2.66) | (2.65) |
| Weighted Avg Shares | 35.25M | 36.1M | 12.12M | 19.51M | 30.38M |
| Weighted Avg Shares (Diluted) | 35.25M | 36.13M | 12.12M | 19.51M | 30.38M |
CAMP4 Therapeutics Corporation
NASDAQ:CAMP
Intrinsic Alpha fair value
Locked
Current Price
$4.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.